At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
Polyphenon E (EGCG)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Green Tea Extract and Prostate Cancer
Louisiana State University Health Sciences Center Shreveport·interventional·Posted May 13, 2008·Updated Aug 8, 2012
In Brief
A Phase 2 clinical trial evaluating Polyphenon E (EGCG) for Prostate Cancer. Completed, enrolled 33 participants across 1 site.
Detailed Summary
The purpose of the study is to see if a green tea extract can beneficially alter several markers of cancer risk and progression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsPolyphenon Pharma
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2004
First PostedMay 2008
Primary CompletionDec 2008
TodayJul 2026
First PostedMay 13, 2008
Enrollment StartMay 1, 2004
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 18.1 years ago
Interventions
Polyphenon E (EGCG)drug
4 capsules daily with a meal for the duration of the study